Provides potency testing to quantify cannabinoid content (e.g., THC, CBD) in cannabis products. Now — the numbers.
This is an established company with proven profits.
Average growth of 34% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $651K would still be left in the vault — a solid cushion for hard times.
The market pays 0.1× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 20% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 34% a year on average.
There is $651K in the vault; even if every debt were paid off, $651K would remain.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.